aTyr Pharma, Inc.

Stock Chart, Company Information, and Scan Results

$6.03(as of Sep 12, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

aTyr Pharma, Inc. Company Information, Fundamentals, and Technical Indicators

Stock Price$6.03
Ticker SymbolATYR
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees56
CountyUSA
Market Cap$590.9M
EBIDTA-69.4M
10-Day Moving Average5.51
P/E Ratio-8.16
20-Day Moving Average5.28
Forward P/E Ratio0.00
50-Day Moving Average5.36
Earnings per Share-0.79
200-Day Moving Average4.14
Profit Margin-Infinity%
RSI62.69
Shares Outstanding98.0M
ATR0.49
52-Week High7.29
Volume16,683,100
52-Week Low1.67
Most Recent Support Level5.08
Book Value74.7M
Most Recent Resistance Level5.77
P/B Ratio7.28
Upper Keltner6.38
P/S RatioInfinity
Lower Keltner4.19
Debt-to-Equity Ratio6.38
Next Earnings DateUnknown
Cash Surplus1.7M
Next Ex-Dividend DateUnknown

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

aTyr Pharma, Inc. In Our Stock Scanner

As of Sep 15, 2025
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.